KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Finished Goods (2016 - 2022)

Historic Finished Goods for TherapeuticsMD (TXMD) over the last 11 years, with Q3 2022 value amounting to $4.5 million.

  • TherapeuticsMD's Finished Goods rose 4235.96% to $4.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $4.5 million, marking a year-over-year increase of 4235.96%. This contributed to the annual value of $2.9 million for FY2021, which is 1229.85% down from last year.
  • Latest data reveals that TherapeuticsMD reported Finished Goods of $4.5 million as of Q3 2022, which was up 4235.96% from $4.0 million recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Finished Goods peaked at $5.0 million during Q3 2019, and registered a low of $1.6 million during Q1 2018.
  • Over the past 5 years, TherapeuticsMD's median Finished Goods value was $3.2 million (recorded in 2019), while the average stood at $3.3 million.
  • In the last 5 years, TherapeuticsMD's Finished Goods soared by 12224.34% in 2019 and then crashed by 3352.29% in 2021.
  • Quarter analysis of 5 years shows TherapeuticsMD's Finished Goods stood at $2.9 million in 2018, then skyrocketed by 71.09% to $5.0 million in 2019, then tumbled by 32.69% to $3.4 million in 2020, then fell by 12.3% to $2.9 million in 2021, then soared by 54.42% to $4.5 million in 2022.
  • Its Finished Goods stands at $4.5 million for Q3 2022, versus $4.0 million for Q2 2022 and $3.3 million for Q1 2022.